Cell Culture Technology– category –
-
EU Project MODICA Innovates Bioprocess Scaling and Semi-Continuous Operation with Adaptive Digital Twin (ADT)
Modica EU Overview MODICA P.S.A., co-funded by EU funds, is developing an innovative Adaptive Digital Twin (ADT) for bioprocess modeling. This system integrates with modular bioreactor hardware components to enable efficient bioprocess s... -
Norwegian University of Life Sciences Offers PhD Scholarship for AI-Driven Digital Twin to Optimize Microbial Lipid Fermentation in Real-time
Jobbnorge Norway Overview The Norwegian University of Life Sciences (NMBU) offers a PhD scholarship focused on developing AI-driven digital twins for real-time optimization and control of microbial lipid fermentation processes. This proj... -
US FDA Approves Only Hematopoietic Stem Cells and Limited Gene Therapies; Warns Against Unapproved Orthopedic and Cosmetic Stem Cell Treatments
Haute Living USA Overview As of 2026, the US FDA has approved only hematopoietic stem cells from umbilical cord blood for blood disorders and a few gene-based stem cell therapies for specific rare genetic diseases. The FDA is actively wa... -
Ultragenyx’s Gene Therapy GENGLYCOS™ for Glycogen Storage Disease Type 1a Receives US FDA Accelerated Approval
RegMedNet USA Overview The US FDA has granted accelerated approval to Ultragenyx Pharmaceuticals' gene therapy, GENGLYCOS™, for adult and pediatric patients aged 8 and older with Glycogen Storage Disease Type 1a (GSD1a). GSD1a is an ultr... -
Thermo Fisher Scientific Seeks Bioprocess Digital Twin Data Scientist for CHO Cell Culture, Accelerating AI-Driven Optimization
Haystack USA Overview Thermo Fisher Scientific is hiring a Data Scientist to lead digital twin model development for CHO cell culture and upstream bioprocess workflows. This role involves hybrid modeling using AI, machine learning, and B... -
Chemically Defined Media and Automation Key to Overcoming Raw Material Variability in Autologous Cell Therapies
BioProcess International International Overview Raw material variability poses a significant challenge to consistent manufacturing and quality in autologous adoptive cell therapies. Overcoming this requires chemically defined media, stan... -
Biologics CDMO Market to Reach $38.29 Billion by 2031, Fill-Finish Emerging as Key Segment
GlobeNewswire Global Overview This article provides an overview of a market research report from GlobeNewswire. The Biologics CDMO market is projected to grow from $27.13 billion in 2026 to $38.29 billion by 2031, exhibiting a CAGR of 7.... -
Point-of-Care Manufacturing Accelerates for Cell and Gene Therapies; Lonza Cocoon Sale Reshapes Industry Landscape
BioPharm International International Overview Point-of-care (PoC) manufacturing for biopharmaceuticals, particularly cell and gene therapies, is gaining momentum, with systems like Lonza's Cocoon and Miltenyi Biotec's CliniMACS Prodigy p... -
Bristol Myers Squibb’s CELMoD Therapy ZENBEXUS™ Receives US FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Business Wire USA Overview Bristol Myers Squibb's novel CELMoD therapy, ZENBEXUS™ (iberdomide), has secured US FDA accelerated approval for relapsed or refractory multiple myeloma patients, including those at first relapse, in combinatio... -
AI Transforms Biotechnology, Advancing Precision Agriculture and Healthcare for Food Security and Sustainability
UMYU Conference on Science, Technology, Engineering, Arts and Mathematics (STEAM) International Overview AI is driving transformative advancements in biotechnology, particularly in bioprocess optimization, genome analysis, and protein st...
